THERANOSTICS 2016* Heike Oberwittler
Ipsen Innovation, , France
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
Phase I/II open-label trial to evaluate the safety and preliminary efficacy of 177Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors (#57)
8:30 AM
Rod Hicks
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours